A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. Male or female participants aged 18 to 60 years (inclusive) at screening.

3. Diagnosis of relapsing MS (RMS) according to the 2017 Revised McDonald criteria (Thompson et al. 2018), including CIS, RRMS or SPMS with disease activity as definedby (Lublin et al. 2014).

4. Disability status at Screening with an EDSS score of 0 to 5.5 (inclusive).

5. Received at least 2 courses of intravenous aCD20 mAb (loading doses are considered 1course):

• Participants currently treated with ocrelizumab must have received (meet all threecriteria below):

1. 2 fully infused initial 300 mg ocrelizumab iv infusions 2. At least 1 fully infused 600 mg ocrelizumab iv infusions 6 months (+/- one month) 3. Last fully infusedocrelizumab dose must have occurred within 4-9 months prior to baseline

•Participants currently treated with rituximab must have received (meet both criteria below):

1. At least 2 fully infused courses of rituximab 500 mg - 1000 mg iv every 6 months (+/- one month).

2. Initial loading regimens of rituximab i.e. 500 mg - 1000 mg on day 1 and on day 15, are allowed but this is consider a single course and must be followed byadditional infusion(s) every 6 months (+/- one month)

3. Last fully infused rituximab dose must have occurred within 4-9 months prior tobaseline.

4. Participants discontinuing aCD20 therapy for reasons including, but not limited to:physician/participant preference, access to commercial drug (e.g. insurance coverageissues) or for other logistical reasons (such as geographical relocation, travel,etc.) are eligible for this study. 7. Neurologically stable within 1 month prior tofirst study drug administration.

5. Must be able to use a smart device or have a caregiver that can assist.

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study:

1. Participants that have demonstrated suboptimal response to aCD20 therapy to include: a. Signs of MRI activity, defined as ≥ 2 active Gd+ T1 lesions, or any new or newlyenlarging T2 lesions, documented within the past 6 months

• If a prior MRI within the last 6 months is not available, then new or newlyenlarging T2 lesions should be considered "not documented" and the patient maycontinue screening b. Documented relapse while on stable, previous aCD20treatment.

• Relapses during the first 3 months of intravenous aCD20 therapy are allowableif the participant is then relapse-free for the 12 months following the relapsewhile on intravenous aCD20 therapy c. Any signs of clinical worsening asmeasured by EDSS or any clinical measure documented within the last 6 months

2. Discontinuing aCD20 mAb therapy due to the following treatment- emergent adverseevents:

3. Severe infusion-related reactions (Grade 3 or above)

4. Recurrent infections defined as ≥ 2 severe infections or ≥ 3 respiratoryinfections or the need for ≥ 2 courses of antibiotics since starting aCD20therapy, if the Investigator believes this is related to therapy.

5. Decreased IgG requiring treatment with Intravenous immunoglobulin

6. Participants with primary progressive MS (Polman et al 2011) or SPMS without diseaseactivity (Lublin et al 2014).

7. Participants meeting criteria for neuromyelitis optica (Wingerchuk et al 2015).

8. Pregnant or nursing (lactating) women

9. Women of child-bearing potential, defined as all women physiologically capable ofbecoming pregnant, unless they are using highly effective methods of contraceptionduring dosing and for at least 6 months after stopping study medication.

10. Participants with active chronic disease (or stable but treated with immune therapy)of the immune system other than MS (e.g. rheumatoid arthritis, scleroderma,Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or withimmunodeficiency syndrome (hereditary immune deficiency, drug-induced immunedeficiency).

11. Participants with active systemic bacterial, viral or fungal infections, or known tohave acquired immunodeficiency syndrome (AIDS).

12. Participants with neurological symptoms consistent with PML or with confirmed PML.

13. Participants at risk of developing or having reactivation of syphilis ortuberculosis

14. Participants at risk of developing or having reactivation of hepatitis.

15. Have received any live or live-attenuated vaccines (including for varicella-zostervirus or measles) within 4 weeks prior to first study drug administration. a. Thereis presently no contraindication for the use of an inactivated, viral-vector-or mRNAbased Sars-CoV-2 vaccine in patients who are immunocompromised. However, differentSars-CoV-2 vaccines may have various mechanisms of action and different associatedpotential risks. Please review local prescribing information of any specificSars-CoV-2 vaccine and comply with local prescribing information requirements forspecific contra-indications and special warnings and precautions for use.